Andere talen Daxor Corporation Nyse

Aandelen

DXR

US2394671034

Beurs gesloten - Nyse Andere beurzen 22:30:01 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,8 ^USD	-0,81%		+1,55%	+2,08%

16/04	Daxor Corporation kondigt twee nieuwe onderzoeken aan die de klinische voordelen van de bloedvolume (BVA-100TM)-diagnostiek van Daxor bevestigen bij ambulante hartfalenpatiënten voor het meten van stuwing	CI
10/04	Daxor Corporation kondigt nieuw ziekenhuisaccount aan bij toonaangevend ziekenhuis in Chicago	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	16/04
Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion	16/04
Daxor Corporation to Exhibit at the Medaxiom Cardiovascular Transforum Conference Spring'24 to Advance Awareness and Further Adoption of Daxor's Blood Volume Diagnostic	16/04
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)	15/04
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	10/04
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital	10/04
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24	01/04
Daxor to Acquire Volumex, Megatope to Increase Diagnostics Suite	25/03
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics	25/03
Daxor Corporation has entered into a definitive agreement to acquire Volumex®, Megatope® and Glofil® from Iso-Tex Diagnostics, Inc.	25/03
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024	22/03
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023	18/03
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders	18/03
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base	11/03
Daxor Corporation Announces Sales to Three New Hospitals Furthering Expansion of Its User Base	11/03
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients	08/03
Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis	08/03
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference	26/02
Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions	12/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Daxor Corporation Nyse

Aandelen

DXR

US2394671034

Andere talen

Filters